228 related articles for article (PubMed ID: 24239348)
1. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo.
Morandell S; Reinhardt HC; Cannell IG; Kim JS; Ruf DM; Mitra T; Couvillon AD; Jacks T; Yaffe MB
Cell Rep; 2013 Nov; 5(4):868-77. PubMed ID: 24239348
[TBL] [Abstract][Full Text] [Related]
2. A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
Song J; Yu J; Jeong LS; Lee SK
Cancer Lett; 2021 Jan; 497():54-65. PubMed ID: 33075425
[TBL] [Abstract][Full Text] [Related]
3. Basic research: MK2 and p53 - a lethal pairing.
Razzak M
Nat Rev Clin Oncol; 2014 Jan; 11(1):3. PubMed ID: 24300879
[No Abstract] [Full Text] [Related]
4. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
Reinhardt HC; Aslanian AS; Lees JA; Yaffe MB
Cancer Cell; 2007 Feb; 11(2):175-89. PubMed ID: 17292828
[TBL] [Abstract][Full Text] [Related]
5. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization.
Reinhardt HC; Hasskamp P; Schmedding I; Morandell S; van Vugt MA; Wang X; Linding R; Ong SE; Weaver D; Carr SA; Yaffe MB
Mol Cell; 2010 Oct; 40(1):34-49. PubMed ID: 20932473
[TBL] [Abstract][Full Text] [Related]
6. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage.
Yang Y; Xia F; Hermance N; Mabb A; Simonson S; Morrissey S; Gandhi P; Munson M; Miyamoto S; Kelliher MA
Mol Cell Biol; 2011 Jul; 31(14):2774-86. PubMed ID: 21606198
[TBL] [Abstract][Full Text] [Related]
7. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints.
Kong YW; Dreaden EC; Morandell S; Zhou W; Dhara SS; Sriram G; Lam FC; Patterson JC; Quadir M; Dinh A; Shopsowitz KE; Varmeh S; Yilmaz ÖH; Lippard SJ; Reinhardt HC; Hemann MT; Hammond PT; Yaffe MB
Nat Commun; 2020 Aug; 11(1):4124. PubMed ID: 32807787
[TBL] [Abstract][Full Text] [Related]
8. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.
Streicher JM; Ren S; Herschman H; Wang Y
Circ Res; 2010 Apr; 106(8):1434-43. PubMed ID: 20339119
[TBL] [Abstract][Full Text] [Related]
9. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
10. Putting the brakes on p53-driven apoptosis.
Höpker K; Hagmann H; Khurshid S; Chen S; Schermer B; Benzing T; Reinhardt HC
Cell Cycle; 2012 Nov; 11(22):4122-8. PubMed ID: 22983126
[TBL] [Abstract][Full Text] [Related]
11. MK2 regulates the early stages of skin tumor promotion.
Johansen C; Vestergaard C; Kragballe K; Kollias G; Gaestel M; Iversen L
Carcinogenesis; 2009 Dec; 30(12):2100-8. PubMed ID: 19808857
[TBL] [Abstract][Full Text] [Related]
12. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
Yego EC; Dillman JF
Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
[TBL] [Abstract][Full Text] [Related]
13. p38 MAP kinase and MAPKAP kinases MK2/3 cooperatively phosphorylate epithelial keratins.
Menon MB; Schwermann J; Singh AK; Franz-Wachtel M; Pabst O; Seidler U; Omary MB; Kotlyarov A; Gaestel M
J Biol Chem; 2010 Oct; 285(43):33242-33251. PubMed ID: 20724476
[TBL] [Abstract][Full Text] [Related]
14. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
15. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
[TBL] [Abstract][Full Text] [Related]
16. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
Jayachandran G; Ueda K; Wang B; Roth JA; Ji L
PLoS One; 2010 Aug; 5(8):e11994. PubMed ID: 20700484
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Yoda A; Toyoshima K; Watanabe Y; Onishi N; Hazaka Y; Tsukuda Y; Tsukada J; Kondo T; Tanaka Y; Minami Y
J Biol Chem; 2008 Jul; 283(27):18969-79. PubMed ID: 18482988
[TBL] [Abstract][Full Text] [Related]
18. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
19. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
20. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
